Q-omics provides the consensus-scored MIR509-3 profile across patient tissues and cancer cell-line models. MIR509-3 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR509-3 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MIR509-3 RNA expression shows 8,824 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where MIR509-3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR509-3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR509-3 survival associations across molecular data types. MIR509-3 RNA expression shows survival associations in the most cancer types (7), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR509-3 RNA expression–survival associations across cancer types. High MIR509-3 expression shows unfavorable associations in LUAD, KIRP, READ and STAD, but favorable associations in KIRC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR509-3 RNA expression.
This table summarizes MIR509-3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR509-3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR509-3 shows higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher MIR509-3 RNA expression in tumor versus normal tissue (log2 FC = +0.649, t-test p < 0.001).
This table shows molecular features associated with MIR509-3 in patient tissues and cancer cell lines. In patient samples, MIR509-3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
